271 related articles for article (PubMed ID: 33509942)
1. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling.
Oh H; Hwang I; Jang JY; Wu L; Cao D; Yao J; Ying H; Li JY; Yao Y; Hu B; Wang Q; Zheng H; Paik J
Cancer Res; 2021 Mar; 81(6):1528-1539. PubMed ID: 33509942
[TBL] [Abstract][Full Text] [Related]
2. PLAGL2-EGFR-HIF-1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity.
Hu W; Zheng S; Guo H; Dai B; Ni J; Shi Y; Bian H; Li L; Shen Y; Wu M; Tian Z; Liu G; Hossain MA; Yang H; Wang D; Zhang Q; Yu J; Birnbaumer L; Feng J; Yu D; Yang Y
Hepatology; 2021 Feb; 73(2):674-691. PubMed ID: 32335942
[TBL] [Abstract][Full Text] [Related]
3. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.
Liu M; Lin Y; Zhang XC; Tan YH; Yao YL; Tan J; Zhang X; Cui YH; Liu X; Wang Y; Bian XW
Lab Invest; 2017 Nov; 97(11):1354-1363. PubMed ID: 28759011
[TBL] [Abstract][Full Text] [Related]
5. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
[TBL] [Abstract][Full Text] [Related]
6. Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
Klingler S; Guo B; Yao J; Yan H; Zhang L; Vaseva AV; Chen S; Canoll P; Horner JW; Wang YA; Paik JH; Ying H; Zheng H
Cancer Res; 2015 May; 75(10):2109-19. PubMed ID: 25808866
[TBL] [Abstract][Full Text] [Related]
7. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
Kurppa KJ; Liu Y; To C; Zhang T; Fan M; Vajdi A; Knelson EH; Xie Y; Lim K; Cejas P; Portell A; Lizotte PH; Ficarro SB; Li S; Chen T; Haikala HM; Wang H; Bahcall M; Gao Y; Shalhout S; Boettcher S; Shin BH; Thai T; Wilkens MK; Tillgren ML; Mushajiang M; Xu M; Choi J; Bertram AA; Ebert BL; Beroukhim R; Bandopadhayay P; Awad MM; Gokhale PC; Kirschmeier PT; Marto JA; Camargo FD; Haq R; Paweletz CP; Wong KK; Barbie DA; Long HW; Gray NS; Jänne PA
Cancer Cell; 2020 Jan; 37(1):104-122.e12. PubMed ID: 31935369
[TBL] [Abstract][Full Text] [Related]
9. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
[TBL] [Abstract][Full Text] [Related]
10. Chaetocin-induced ROS-mediated apoptosis involves ATM-YAP1 axis and JNK-dependent inhibition of glucose metabolism.
Dixit D; Ghildiyal R; Anto NP; Sen E
Cell Death Dis; 2014 May; 5(5):e1212. PubMed ID: 24810048
[TBL] [Abstract][Full Text] [Related]
11. lncRNA KCNQ1OT1 promotes proliferation and invasion of glioma cells by targeting the miR‑375/YAP pathway.
Ding P; Liang B; Shou J; Wang X
Int J Mol Med; 2020 Dec; 46(6):1983-1992. PubMed ID: 33125099
[TBL] [Abstract][Full Text] [Related]
12. EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy.
Xia H; Dai X; Yu H; Zhou S; Fan Z; Wei G; Tang Q; Gong Q; Bi F
Cell Death Dis; 2018 Feb; 9(3):269. PubMed ID: 29449645
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Yang Z; Zhang SL; Hu X; Tam KY
Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
[TBL] [Abstract][Full Text] [Related]
14. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
15. Long non‑coding RNA LINC00473/miR‑195‑5p promotes glioma progression via YAP1‑TEAD1‑Hippo signaling.
Wang X; Li XD; Fu Z; Zhou Y; Huang X; Jiang X
Int J Oncol; 2020 Feb; 56(2):508-521. PubMed ID: 31894297
[TBL] [Abstract][Full Text] [Related]
16. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1.
Chen G; Chen Z; Zhao H
J Cell Mol Med; 2020 May; 24(9):5363-5374. PubMed ID: 32220051
[TBL] [Abstract][Full Text] [Related]
18. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
19. IFN‑β sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells.
Yoshimura S; Sano E; Hanashima Y; Yamamuro S; Sumi K; Ueda T; Nakayama T; Hara H; Yoshino A; Katayama Y
Oncol Rep; 2019 Dec; 42(6):2635-2643. PubMed ID: 31638255
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of 13-cis retinoic acid-induced gene expression of reactive-resistance genes by thalidomide in glioblastoma tumours in vivo.
Milanovic D; Sticht C; Röhrich M; Maier P; Grosu AL; Herskind C
Oncotarget; 2015 Oct; 6(30):28938-48. PubMed ID: 26362268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
